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Abstract: The BCR-ABL kinase inhibitor imatinib mesylate is currently the standard therapy 
for patients with chronic myeloid leukemia (CML). Despite the remarkable results achieved 
with imatinib for the treatment of CML, the emergence of resistance to this drug has become 
a signiﬁ  cant problem. Mutations within the ABL kinase domain have been identiﬁ  ed as the 
main mechanism of resistance to imatinib. Other mechanisms include genomic ampliﬁ  cation 
of BCR-ABL and modulation of drug efﬂ  ux or inﬂ  ux transporters. Several strategies have been 
developed to overcome the problem of imatinib resistance, including dose escalation of ima-
tinib, combination treatments, or novel targeted agents. Nilotinib is a tyrosine kinase inhibitor 
30-fold more potent than imatinib, active against a wide range of mutant clones, except T315I. 
Phase I–II trials of nilotinib showed high activity in imatinib-resistant CML and Ph+ acute 
lymphoblastic leukemia. We here review the development of nilotinib and the activity of this 
agent in CML patients and in other forms of sensitive neoplasms.
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Introduction
Chronic myelogenous leukemia (CML) is a clonal disorder caused by the malignant 
transformation of a pluripotent hematopoietic stem cell. It is characterized by the 
Philadelphia chromosome (Ph), a genetic abnormality which arises from the recipro-
cal translocation t(9; 22) (q34; q11) (Faderl et al 1999). This translocation fuses the 
genes encoding BCR and ABL, resulting in expression of the constitutively active 
protein tyrosine kinase, BCR-ABL. The Ph chromosome is present in more than 
90% of adult CML patients, in 15%–30% of adult acute lymphoblastic leukemia 
(ALL), and in 2% of acute myelogenous leukemia (AML) (Goldman and Melo 
2003). Different molecular weight isoforms are generated, based on different break-
points and mRNA splicing. Most CML patients have a fusion protein of 210 kDa 
while approximately 30% of Ph+ ALL cases and few CML cases are associated to 
190 kDa BCR-ABL protein (Sattler et al 2003). CML normally progresses through 
three clinically recognized phases: about 90% of patients are diagnosed during the 
typically indolent chronic phase (CP), which is followed by an accelerated phase 
(AP) and a terminal blastic phase (BP). Twenty to 25% of patients progress directly 
from CP to BP and the time course for progression can be extremely varied. The 
mechanisms behind CML progression are not fully understood (Goldman and Melo 
2003). There is increasing evidences that Src family kinases are involved in CML 
progression through induction of cytokine independence and apoptotic protection 
(Donato et al 2003).
The function of BCR-ABL has allowed the design and development of imatinib, 
a small-molecule kinase inhibitor that targets PDGFR, c-Kit, and ABL kinases OncoTargets and Therapy 2008:1 50
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(Deininger et al 2005). Imatinib provides an effective and 
durable therapy for CML: a recent 6-year follow-up of 
phase III International Randomized IFN versus STI571 
(IRIS) study, showed that this agent induced complete 
hematologic remission in the majority (98%) of newly 
diagnosed patients in chronic phase of the disease and com-
plete cytogenetic remission (CCR) in about 87% of patients 
(Druker et al 2006).
With the high rate of complete cytogenetic responders, 
the goal of therapy has become the achievement of molecular 
responses, as measured by the reduction or elimination of 
BCR-ABL transcript. Major molecular response (MMR) in 
the IRIS trial was deﬁ  ned as a 3 log reduction in transcript 
from baseline. Obtaining MMR was associated with signiﬁ  -
cantly better long-term remission duration and progression-
free survival (PFS). At 60-month follow-up, achievement 
of CCR and MMR by 12 months was associated with a PFS 
of 97% compared with 89% for patients with CCR but with 
less MMR (Druker et al 2006). Early molecular response 
predicted a better outcome: progression of disease correlated 
with failure to achieve a 1 log reduction in transcript level 
by 3 months and a 2 log reduction by 6 months (Druker 
et al 2006).
In 2006, recommendations for deﬁ  nitions of failure/
resistance and suboptimal response to imatinib were pro-
posed by European LeukemiaNet (Baccarani et al 2006); 
failure was deﬁ  ned as no complete hematologic response 
at 3 months, no cytogenetic response at 6 months, less than 
partial cytogenetic response at 12 months, less than com-
plete cytogenetic response at 18 months, or loss of complete 
hematologic response (CHR) or CCR, or acquisition of 
BCR-ABL mutations at any time. Suboptimal response was 
deﬁ  ned as incomplete hematologic response at 3 months, less 
than partial CR at 6 months, less than complete cytogenetic 
response at 12 months, and less than MMR at 18 months, or 
acquisition of cytogenetic abnormalities in Ph+ cells, muta-
tions of BCR-ABL or loss of MMR at any time (Baccarani 
et al 2006).
Despite the apparent success of imatinib therapy, the IRIS 
study at 5 years follow-up provides an indication of imatinib 
failure: 31% of patients have discontinued imatinib, with an 
estimated resistance (lack or loss of response) of 14% (Druker 
et al 2006). The estimated annual rate of treatment failure 
after the start of imatinib therapy was 3.3% in the ﬁ  rst year, 
7.5% in the second year, 4.8% in the third year, 1.5% in the 
fourth year, and 0.9% in the ﬁ  fth year. The corresponding 
annual rates of progression to AP or BP were 1.5%, 2.8%, 
1.6%, 0.9%, and 0.6%, respectively.
Resistance can be deﬁ  ned on the basis of its time of 
onset: primary resistance is a failure to achieve a signiﬁ  cant 
hematologic or cytogenetic response, whereas secondary 
or acquired resistance is the progressive reappearance of 
the leukemic clone after an initial response to the drug 
(Baccarani et al 2006). Resistance is also deﬁ  ned on the 
basis of clinical and laboratory criteria used for detection of 
leukemia, which includes hematological, cytogenetic, and 
molecular resistance. Hematological resistance is a lack of 
normalization of peripheral blood counts and spleen size; 
cytogenetic resistance is a failure to achieve a major cyto-
genetic response; and molecular resistance represents the 
failure to achieve or loss of complete or MMR (Hochhaus 
and La Rosee 2004).
Several mechanisms may contribute to imatinib resis-
tance, including increased expression of BCR-ABL kinase 
through gene ampliﬁ  cation, decreased intracellular drug 
concentrations caused by drug efﬂ  ux proteins (OCT1), clonal 
evolution, or over-expression of Src kinases (Lyn, Hck) 
involved in BCR-ABL independent activation of alternative 
pathways (Apperley 2007). Emergence of clones expressing 
mutant forms of BCR-ABL, in which amino acid substitu-
tions in the ABL kinase domain impair imatinib binding 
trough disruption of critical contact point by inducing a 
switch from the inactive to active conformation are the most 
frequent cause of resistance.
The ﬁ  rst reported clinical resistance BCR-ABL mutation 
was T315I, a single amino acid substitution of the threonine 
315 residue to an isoleucine: this blocked imatinib binding 
by suppressing a drug kinase hydrogen bond and by creating 
a steric clash between imatinib and the bulky hydrocarbon 
side chain of the isoleucine residue in the mutant, while 
preserving the ATP-binding and kinase activity of the 
BCR-ABL protein. To date, more than 50 different point 
mutations encoding for more than 40 distinct single amino 
acid substitutions in the BCR-ABL kinase domain have 
been isolated from CML-relapsed patients, and preclinical 
studies have demonstrated that mutations outside the domain 
can also result in molecular conformations of BCR-ABL 
that impair imatinib binding. Mutations are more frequent 
in patients with acquired resistance compared with primary 
resistance patients, whereas in early CP patients they are rare 
(Hochhaus et al 2007).
Early detection of BCR-ABL mutants may identify 
patients who are likely to become resistant to imatinib 
therapy, in whom optimization of treatment such as dose 
escalation, drug combination, or second-generation tyro-
sine kinase inhibitors are requested. There is currently no OncoTargets and Therapy 2008:1 51
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consensus on which technique should be used for muta-
tion analysis screening, and highly sensitive detection 
methods can increase the detection rate of point mutations. 
Allele speciﬁ  c oligonucleotide polymerase chain reaction 
methods have permitted the detection of mutants prior 
to imatinib therapy. Mutations can also be detected in an 
automated manner by denaturing high-performance liquid 
chromatography (DHPLC), which has been described as 
a highly sensitive screening method, even when the site of 
mutation is unknown (Baccarani et al 2008). Recent work 
by Ernst et al (2008) proved that the occurrence of mutations 
during imatinib therapy is predictive of relapse and that 
mutations may be detectable several months before relapse; 
their identiﬁ  cation could provide clinical beneﬁ  t for patients 
and lead to early reconsideration of therapeutic strategies 
(Ernst et al 2008).
Higher doses of imatinib and combination therapy 
with other agents have been used to overcome imatinib 
resistance (Kantarjian et al 2003). Imatinib dose escalation 
is an accepted clinical strategy, and doubling the dose in 
patients treated with standard dose allowed hematological 
and cytogenetic responses in half of patients treated with this 
procedure. Some investigators have questioned the durability 
of responses after imatinib dose escalation (Marin et al 2003; 
Zonder et al 2003). Increasing the dose of imatinib is likely 
useful only in a subset of patients with imatinib cytogenetic 
resistance, whereas alternative treatment options are required 
for the other subset of resistant patients.
A series of compounds commonly referred to as second-
generation tyrosine kinase inhibitors, have been developed 
to improve the results obtained with imatinib. In this article, 
we provide an overview of development and clinical results 
of nilotinib, a new tyrosine kinase inhibitor that received 
approval by US Food and Drug Administration (FDA) on 
October 2007, for the use in treatment of patients with CP 
and AP CML resistant or intolerant to imatinib.
Development and biochemical 
and molecular characterization 
of nilotinib
The development of nilotinib was based upon the crystal 
structure of the imatinib-ABL complex (Figure 1, Schindler 
et al 2000; Manley et al 2004). Based on these structural data, 
a more potent and selective compound could be designed 
by incorporating alternative binding groups for the N-
methylpiperazine group, while retaining an amide pharmaco-
phore to keep the H-bond interactions to Glu286 and Asp381 
(Manley et al 2004). This approach resulted in the discovery 
of AMN107, or nilotinib. Nilotinib has superior potency 
compared with imatinib as an inhibitor of BCR-ABL in vitro 
and in vivo: it is 10- to 30-fold more potent, as assessed by 
its ability to block proliferation of BCR-ABL dependent cell 
lines derived from CML patients (K562, Ku-812F) and cell 
lines (32D or Ba/F3) transfected to express the BCR-ABL 
protein (Figure 2; Weisberg et al 2005). Similarly, nilotinib 
is 10- to 20-fold more active than imatinib in reducing 
BCR-ABL autophosphorylation (IC50 values ranging from 
20–60 nM). Unlike imatinib, this drug makes only four 
hydrogen-bond interactions with the ABL kinase domain, 
involving the pyridyl-N and the backbone-NH of Met 318, 
the anilino-NH and the side chain hydroxyl of Thr315, the 
amido-NH and side chain carboxylate of Glu 286 and the 
amido C = O with the backbone-nh of the Asp 381 (Manley 
et al 2005). The increased potency of nilotinib against ABL 
is the result of a better ﬁ  t with the active site in the kinase 
domain. Like imatinib, nilotinib binds the hydrophobic pocket 
referred to as the DGF (asparagines, glycine, phenylalanine) 
Figure 1 The molecular structures of nilotinib (B) and imatinib (C) are depicted, with their respective H-bond interactions with the ABL kinase domain (red).OncoTargets and Therapy 2008:1 52
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motif, which is displaced away from the ATP-binding site 
(DGF-out) upon adoption of the active conformation by the 
BCR-ABL kinase (Hubbard et al 1994; Liu and Gray 2006). 
This speciﬁ  c mode of binding is the basis of the selectivity 
of imatinib and nilotinib. Nilotinib also inhibits the tyrosine 
kinase activity of the PDGF and c-Kit receptors, displaying 
similar efﬁ  cacy to imatinib, and possessing greater selectivity 
toward BCR-ABL. Nilotinib showed no activity against a 
wide panel of other protein kinases at concentrations below 
3 μM, including c-Src.
Nilotinib is more potent 
than imatinib against BCR-ABL 
mutant isoforms: in vitro results
Nilotinib is 30-fold more potent than imatinib in the 
killing of wild-type BCR-ABL expressing cells (Manley 
et al 2005; Weisberg et al 2005), and 43- to 60-fold more 
potent than imatinib against cell lines KBM5 and KBM7 
(Golemovic et al 2005). It has no activity against T315I even 
at concentrations up to 10 μM: as with imatinib, the lack 
of activity against T315I is the result of nilotinib binding 
closely to the T315 residue, such that loss of the hydroxyl side 
chain and additional methyl group of the isoleucine inhibits 
binding (O’Hare et al 2005). Four mutant isoforms (E255K, 
E255V, L248R, Y253H) were found to confer intermediate 
sensitivity to nilotinib when transfected into Ba/F3 cells 
(Weisberg et al 2005). In vitro activity was demonstrated 
in severe combined immune-deﬁ  cient mice (NOD-SCID) 
subjected to sublethal doses of radiation and transplanted 
with murine p210 positive cells engineered to express muta-
tions; activity was demonstrated also in bone marrow cells 
from normal mice transduced with normal and mutant cells 
(E255V): treatment with nilotinib prolonged survival and 
reduced the accumulation of leukemic cells in the spleen, 
bone marrow, lymphonodes and liver (Weisberg et al 2005). 
Recently, using cell-based screening, it was identiﬁ  ed which 
mutants might arise under nilotinib therapy: in contrast to 
imatinib, resistance to nilotinib was associated with a limited 
spectrum of BCR-ABL kinase mutations. With the excep-
tion of T315I, all of the mutations that were identiﬁ  ed were 
effectively suppressed when the nilotinib concentration was 
increased to 2,000 nM, which is the peak of range of plasma 
concentration measured in patients treated with 400 mg twice 
daily. Resistance mutations that may arise in condition of 
suboptimal nilotinib concentration include p-loop mutations, 
such as Y253H and E255V. Because plasma levels of up to 
3,600 nM were measured in phase I and II, p-loop mutations 
may emerge less frequently than with imatinib therapy and it 
is expected that nilotinib induces responses in cases in which 
p-loop mutations cause resistance to imatinib mesylate (von 
Bubnoff et al 2006).
With a N-ethyl-N-nitrosourea (ENU)-based mutagenesis 
screen, imatinib, nilotinib, and dasatinib (a 325-fold more 
potent inhibitor active against BCR-ABL and src kinases 
family) were compared; 20 different mutations were recov-
ered upon treatment with imatinib, while only 10 and 9 
were recovered after exposure to nilotinib or dasatinib, 
respectively. The mutations recovered after exposure to 
intermediate concentrations of nilotinib included T315I, 
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Figure 2 Activity of nilotinib against 32D.p210- and 32D-E255V-Luc+ cells in vivo. Adapted from Weisberg E, Manley PW, Breitenstein W, et al. 2005. Characterization of 
AMN107, a selective inhibitor of native and mutant BCR-ABL. Cancer Cell, 7:129–41. Copyright © 2005 with permission from Elsevier.OncoTargets and Therapy 2008:1 53
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Y253H, and E255V, whereas at concentrations close to 
the maximal achievable plasma levels, only T315I was 
isolated (Bradeen et al 2006). In 2007, Ray et al conducted 
a saturation mutagenesis screening for nilotinib-resistant 
BCR-ABL subclones, using a method previously described 
by Azam et al and Cools et al for imatinib against BCR-ABL 
and PKC412 against FLT3 (Ray et al 2007; Azam et al 2003; 
Cools et al 2004). With the exception of T315I, all mutations 
detected in this study were inhibited by nilotinib plasma level 
concentrations: this suggested that the clinical resistance 
to nilotinib might be predominantly associated with the 
emergence of T315I. The results of the mutagenesis screen 
also indicated that the mutations of the p-loop, C-helix, SH2 
contact, and the A-loop might occur less frequently or would 
be manageable with moderate dose escalation of nilotinib 
(Ray et al 2007).
Synergistic effects between imatinib 
and nilotinib
Based on previously a described interaction between 
imatinib and nilotinib in mouse expressing p210 positive 
cells, Weisberg et al showed positive cooperative effects of 
combination of nilotinib with imatinib in a panel of imatinib-
sensitive and imatinib-resistant BCR-ABL expressing cells 
in vitro: the result was a synergistic/additive effect against 
Ba/F3 cells carrying multiple point mutations, such as E255V, 
E255K, F317L, M351T, and F486S, but not against Y253H 
or T315I (Weisberg et al 2007). Recent studies of White et al 
(2007) using 14C-labeled imatinib and nilotinib in an assay 
measuring intracellular uptake and retention (IUR), assessed 
the effect of adding unlabeled nilotinib to the 14C-labeled ima-
tinib IUR and, conversely, unlabeled imatinib to 14C-labeled 
nilotinib IUR. While there was variation in the degree of 
response between patients, the data demonstrated a signiﬁ  cant 
increase in the IUR of 1 μM 14C-labeled nilotinib when either 
1 or 2μM imatinib was added. Other experiments by White 
et al assessing the effect of temperature (37 °C vs 4 °C) on 
nilotinib uptake and retention in an ABCB1-expressing cell 
line suggested that nilotinib is transported by ABCB1. There-
fore, imatinib inhibition of ABCB1-mediated efﬂ  ux may be 
the cause for the increased IUR for nilotinib that is observed 
when both drugs are combined (White et al 2007).
Application of nilotinib: phase I 
studies in CML
In a phase I dose-escalation study, nilotinib was given to 
119 patients with imatinib-resistant CML or acute lympho-
blastic leukemia (17 patients in CP, 56 in AP, 24 in myeloid 
BP, 22 in lymphoid BP or Ph+ ALL). Daily doses ranged from 
50 to 1,200 mg once daily or 400 mg and 600 mg twice daily, 
and were assigned in 9 dose cohorts of patients, to evaluate the 
safety and tolerability of the drug (Table 1). Dose escalation 
was permitted for patients with inadequate response and no 
toxic effects. The maximum tolerated dose was established 
at 600 mg twice daily. The treatment was established for 
a median duration of 120 days (range 1–385). Complete 
blood count was obtained weekly for the ﬁ  rst 8 weeks and 
then every other week. Patients were evaluated for cytoge-
netic analysis at baseline and if they had response. Safety 
assessment included evaluation of side effects, hematologic 
and cardiac assessment, electrocardiography, and physical 
examination. Pharmacokinetic study revealed that the median 
time to peak nilotinib concentrations was 3 hours, the half-
life was 15 hours, and the steady state level was achieved by 
day 8. With a daily dose, the peak concentrations and the area 
under the concentration-time curve increased among patients 
receiving a daily dose of 400 mg and reached a plateau among 
patients receiving more than 400 mg. Four hundred mg and 
600 mg were administered twice daily and tested in 32 and 
18 patients, respectively. The mean serum trough level at 
the steady-state level was 1.0 μM at 400 mg daily, 1.7 μM at 
400 mg twice daily, and 2.3 μM at 600 mg twice daily, all of 
these concentrations exceeding the IC50 of cellular phosphor-
ylation of 32 of 33 BCR-ABL kinase mutants (19–709 nM). 
No differences were observed between patients with or with-
out BCR-ABL mutations, except for 2 patients with T315I 
mutation who exhibited marked resistance to nilotinib. The 
most frequent grade 3–4 toxicities were hematologic, with 
thrombocytopenia occurring in 21% and neutropenia in 14% 
of patients. The non-hematologic proﬁ  le was similar to that 
Table 1 Phase I and II results
Response rate (%)
CML 
phase
No of 
patients
CHR Major 
cytogenetic 
response
Complete 
cytogenetic 
response
Phase I CP 17 92 35 35
AP 56 51 27 14
My BP 24 8 21 4
Ly BP 22 0 11 11
Phase II CP 387 77 57 41
AP 129 26 31 19
My BP 105 11 38 29
Ly BP 31 13 48 32
Abbreviations: AP, accelerated phase; BP, blastic phase; CP, chronic phase; CHR, 
complete hematologic response; CML, chronic myeloid leukaemia.OncoTargets and Therapy 2008:1 54
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of imatinib and included peripheral oedema, weight gain, and 
cutaneous rash. Grade 3–4 unconjugated bilirubinemia was 
reported in 14% of patients receiving 600 mg twice daily: 
this increase was not accompanied by an increase in levels 
of amino-transferase or evidence of increased hemolysis. 
Grade 3–4 elevations of lipase occurred in 5% of patients and 
grade 3 elevation of amylase level was reported in 1 patient. 
From more than 2,200 electrocardiograms performed in a 
cohort of 119 patients, the only abnormality associated with 
the drug was the corrected QT interval by Fridericia’s for-
mula, which was increased from 5 to 15 msec. Furthermore, 
pericardial effusion and atrial ﬁ  brillation were described in 1 
patient. The evaluation of the responses showed that among 
17 CP patients, 9 (53%) had a cytogenetic response, including 
6 patients with CCR and 3 patients with minimal response. 
CHR occurred in 92% of CP patients. Among AP patients, 
72% of  those with hematologic disease obtained a CHR: a total 
of 55% of patients obtained a cytogenetic response, which was 
complete in 8 patients, partial in 7, and minor in 5. Among 
patients with myeloid BP, 42% achieved a CHR and 29% a 
cytogenetic response (1 patient CCR); of the 9 patients with 
lymphoid BP or Ph+ ALL, 33% achieved a CHR and 22% 
a cytogenetic response (1 patient CCR). In patients with AP 
or BP who received nilotinib 400 mg or 600 mg twice daily, 
a signiﬁ  cant decrease in phosphorylation of AKT, CRKL, 
STAT1, and STAT5 was observed on day 15 of therapy 
compared with baseline (Kantarjian et al 2006).
Jørgensen et al had reported on the efﬁ  cacy of nilotinib 
on CD34+ CML cells: in this subset, imatinib and nilotinib 
were equipotent for the inhibition of BCR-ABL activity, and 
produced equivalent effect but incomplete reduction in CRKL 
phosphorylation at 5 μM. As for imatinib, the most primitive 
cells persisted and accumulated over 72 hours with nilotinib, 
and remained caspase-3 negative. The combination of nilo-
tinib and imatinib produced further accumulation of this 
cell population, suggesting additive antiproliferative effects 
(Jørgensen et al 2007). Recently, it was demonstrated that 
nilotinib inhibited mitogen-activated protein kinase (MPAK), 
AKT and STAT5 phosphorylation in CML CD34+ cells in 
the absence of growth factors, but did not suppress AKT and 
STAT5 activity and resulted in increased MAPK activity in 
the presence of growth factors. For this reason nilotinib did 
not show increased efﬁ  cacy in reducing non-dividing CML 
progenitors compared with imatinib (Konig et al 2008).
Phase II studies
Results from a phase I dose escalation study indicated that 
nilotinib produces signiﬁ  cant hematologic and cytogenetic 
responses in all phases of CML (Table 1). The primary end-
points of a phase II study was to determinate the rate of major 
cytogentic response in patients with CP after resistance or 
intolerance to imatinib. A ﬁ  rst draft from an interim analysis 
on the ﬁ  rst 280 consecutively enrolled CP-CML patients was 
published in 2007 (Kantarjian et al 2007a). Based on phar-
macokinetic study of phase I, nilotinib was administered at 
400 mg twice daily and could be escalated to 600 mg twice 
daily if patients had not obtained an hematologic response 
at 3 months, a major cytogenetic response at 12 months, or 
if they showed loss of hematologic or cytogenetic response 
or disease progression at any time. A total of 318 patients 
were enrolled and treated at 63 different institutions. The 
results referred to the initial cohort of 280 patients with at 
least 6 months of follow up: 194 (69%) patients were imatinib 
resistant and 86 (31%) patients were imatinib intolerant. 
Nilotinib was interrupted at a very low rate (median days 
18) and the median intensity of nilotinib was 797 mg/day, 
very close to the intended daily dose of 800 mg/day. Sixty-
ﬁ  ve percent of patients remained on study, with the main 
causes of discontinuation being adverse events (15%) and 
disease progression (11%). Complete hematologic response 
was achieved in 68% of patients with resistance and 90% of 
patients with intolerance to imatinib, with a total response 
of 74%. Rates of major cytogenetic responses were 48% in 
patients with imatinib intolerance and 47% in patients with 
imatinib resistance. Complete cytogenetic response was 
reached in 30% of patients with imatinib resistance and in 
47% of patients with imatinib intolerance (overall 31%); 
in addition 2% of patients entered the study while in CCR 
and maintained the response and 1% had missing baseline 
assessment but CCR was detected during the study. Partial 
cytogenetic response was achieved in 16% of patients overall 
(19% in imatinib-resistant and 12% in imatinib-intolerant); 
in addition 1% of patients entered the study while in PCR 
and maintained this response. Rate of patients that persisted 
in MCR was 96% (only 5 out of 134 patients discontinued 
therapy due to progression or death) and estimated 1-year 
overall survival was 95% (a total of 10 patients died: 2 during 
treatment and 8 during the long term follow up). Mutational 
study was available for 182 patients and 28 different muta-
tions were detected: MCR was achieved in 42% of mutated 
patients (versus 51% of non-mutated) and CCR was achieved 
in 23% of mutated patients (versus 35% of non-mutated). 
CHR and MCR were observed across all BCR-ABL geno-
types, with the exception of the T315I mutation, identiﬁ  ed in 
4 patients, and the E255V and E274K mutations, identiﬁ  ed in 
1 patient each. The rates of responses appeared to be affected OncoTargets and Therapy 2008:1 55
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by preclinical IC50 to nilotinib: patients with mutations with 
IC50 less than 100 nM reached MCR at a rate of 53% versus 
15% of patients with mutations with IC50 ranging from 
201 to 800 nM. Patients with IC50 more than 10,000 nM 
did not achieve cytogenetic response. The patients with less 
sensitive mutations (IC  200 nM) showed complete in vitro 
suppression with increased exposure to nilotinib. It is possible 
that, as suggested by Kantarjian et al (2007a), longer treat-
ment duration may result in further improvement in clinical 
responses in patients with less sensitive mutations.
The safety proﬁ  le was similar to that observed in the 
phase I study. The majority of serum chemistry abnormali-
ties ranged from mild to moderate and included elevations of 
AST/ALT in 4% of patients and elevations of bilirubin and 
lipase, occurred in 9% and 14% of patients, respectively. The 
etiology of hyperbilirubinemia was explored in 62 patients 
by examining the polymorphisms in the uridine diphosphate 
glucurosyltransferase 1A1 (UGT1A1) gene: the results 
indicated that the repeat of TA, which predisposes to Gilbert 
syndrome, predicted for susceptibility to side effect under 
nilotinib. Comparison of non-hematologic adverse events 
occurred in patients with imatinib-intolerance subsequently 
treated with nilotinib, showed the presence of a same effect 
in only 2 out of the 86 observed patients, thus indicating the 
lack of cross-intolerance between the two drugs. Preclinical 
studies showed that nilotinib could potentially prolong the 
QT interval: an incidence of 1% of QTc intervals exceed-
ing 500 milliseconds according to Fridericia correction was 
reported. Pleural effusions were observed in only 1% of 
patients on nilotinib therapy (Kantarjian et al 2007a).
The same phase II multicenter international single arm 
study also examined the efﬁ  cacy and safety of nilotinib in 
patients with accelerated phase resistant or intolerant to 
imatinib. AP was deﬁ  ned by one or more of the following 
features: 15% but 30% blasts in the bone marrow or in 
blood, 30% blasts plus promyelocytes in blood or bone 
marrow, peripheral blood basophils 20%, and/or throm-
bocytopenia 100 × 109/L unrelated to therapy. All patients 
were initially treated with nilotinib 400 mg twice daily and 
dose escalation to 600 mg twice daily was permitted for 
failure to obtain return to CP by 1 month, loss of an achieved 
hematologic or cytogenetic response, or disease progression. 
Primary endpoint was the rate of hematologic responses, 
deﬁ  ned as CHR, bone marrow response, or return to CP. 
Secondary endpoints included time to hematologic response, 
duration of hematologic response (HR), MCR, time to and 
duration of MCR, and overall survival. A total of 119 patients 
from 36 different institutions were enrolled: the majority had 
received previous therapy other than imatinib and 81% of all 
patients were imatinib resistant, with 49% previously treated 
with at least 800 mg. Among the 119 patients an overall 
HR rate of 47% was observed in a median of 1 month of 
treatment. Of these patients who achieved HR, 70% remained 
in response at 12 months. In a median of 2 months of treat-
ment, 35 patients (29%) achieved a MCR and 19 patients 
(16%) a CCR. Median duration of MCR was 15.4 months. 
Thirty-ﬁ  ve patients with additional chromosome abnor-
malities (ACA) at baseline were included in the study: 21 of 
them responded (60%), similarly to patients without ACA. 
The estimated 1-year overall survival was 79%. Mutational 
screening was available for 51 patients and 17 different 
BCR-ABL mutations were identiﬁ  ed. HR was obtained in 
48% of mutated patients compared with 45% of non-mutated, 
and MCR was achieved in 21% of mutated versus 36% of 
non-mutated patients. HR and MCR were observed across 
a variety of BCR-ABL mutant genotypes. The T315I muta-
tion was the only one imatinib resistant among 32 tested 
mutations. The most commonly reported non-hematologic 
events possibly related to nilotinib were rash (22%), pruritus 
(20%), constipation (11%), nausea, headache, and fatigue 
(10%). The most common hematologic adverse events of 
grade 3–4 were thrombocytopenia (35%) and neutropenia 
(21%). The serum biochemistry abnormalities observed 
were mild to moderate, and grade 3–4 elevations in AST and 
ALT were recorded in 1% and 2% of patients, respectively. 
Grade 3–4 elevations in bilirubin occurred in 9% and lipase 
in 18% of patients. No patients experienced a prolongation 
in QTc interval. Estimated 1-year overall survival was 79% 
(Le Coutre et al 2008).
Results of nilotinib treatment in patients with Ph+ CML 
in blast crisis (CML-BC) resistant to or intolerant of imatinib 
were presented at ASH 2007 (Giles et al 2007). The primary 
endpoint was a conﬁ  rmed HR. Nilotinib was given at the 
dose of 400 mg twice daily with the possible dose escalation 
to 600 mg twice daily for inadequate response. Data were 
presented for 135 patients with blast crisis (BC) (103 myeloid 
and 29 lymphoid). Hematologic response was recorded in 39% 
of myeloid BC patients and in 38% of lymphoid BC patients, 
with 5% of marrow response being observed in myeloid BC 
and in 3% in lymphoid BC. The most common grade 3–4 
hematologic abnormalities were neutropenia (67%), thrombo-
cytopenia (62%), and anemia (42%). The most common grade 
3–4 non-hematologic side effects were: pneumonia (11%), 
pyrexia (7%), nausea (4%), diarrhea (4%), and asthenia (4%). 
Nilotinib was administered at a dose of 400 mg twice daily 
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previously received and either failed or were intolerant to both 
imatinib and dasatinib (Giles et al 2007). A total of 67 patients 
were reported with CML-CP (27), CML-AP (15), and CML-BP 
(25 total; 15 myeloid, 8 lymphoid). A total of 22 (33%) patients 
with dasatinib failure remained on nilotinib and 45 (67%) 
discontinued. Of 17 patients with CML-CP who did not have 
a CHR at baseline, 11 (65%) achieved a CHR at 4-month fol-
low up. Of all 22 CML-CP patients, 7 (32%) had a MCR (3 
complete, 4 partial). Of 13 patients with CML-AP, 3 (23%) 
showed no evidence of leukemia and 3 (23%) had a return to 
chronic phase after 4 months of nilotinib therapy. Of 20 patients 
with BP, 3 (15%) achieved CHR, 1 (5%) had return to CP, and 
6 (30%) had disease progression. The most common grade 3/4 
hematologic adverse events reported were neutropenia (51%), 
thrombocytopenia (44%), and anemia (21%). The most frequent 
grade 3–4 non-hematologic adverse events were pyrexia (8%), 
anorexia and headache (3%), diarrhoea, asthenia, constipation, 
fatigue, and myalgia (2% each) (Giles et al 2007).
Recently, the MD Anderson group described the outcome 
of 420 patients after imatinib failure, with 374 of them being 
resistant and 46 intolerant to the drug. Prognosis in this sub-
set of patients is usually reported to be poor, but there are 
no data on survival after subsequent treatments with stem 
cell transplant or new TKI. In the cohort of 88 patients with 
CP, median survival was not reached in this study and the 
estimated 3-year survival rate was 72%. Prognosis was better 
after receiving dasatinib or nilotinib versus allogeneic stem 
cell transplantation (SCT) versus other therapies for patients 
in CP, but not for patients in more advanced phase of disease 
(Kantarjian et al 2007b).
The activity of nilotinib is currently being evaluated in the 
frontline setting of CP patients. Preliminary results were pre-
sented at the 2007 ASH meeting (Cortes et al 2007): 32 patients 
with early CP received 400 mg twice daily; Sokal risk was 
low in 21 patients, intermediate in 6, and high in 3. The rates 
of CCR at 3, 6, and 12 months were 95%, 100%, and 100%, 
respectively, and compared favorably with those observed in 
historical control patients treated with imatinib at 400 and 800 
mg. MMR was achieved by 3 patients at 3 months, by 7 patients 
at 6 months, and by 5 patients at 12 months. Grade 3–4 neutro-
penia and thrombocytopenia were observed in the rate of 7% 
and 3%, respectively. Other grade 3–4 adverse events included 
elevation of lipase, bilirubin, and back pain. Twelve patients 
had treatment interruptions due to pain and lipase elevation. 
Only 3 patients discontinued therapy: 2 switched to imatinib 
and 1 performed SCT (Cortes et al 2007).
A biomarker study using the established pCRKL assay in 
imatinib-resistant CML and Ph+ ALL treated with nilotinib 
was recently published (La Rosee et al 2008). With this study 
a minimun dose (200 mg) required for effective BCR-ABL 
inhibition in imatinib-resistant/intolerant leukemia was estab-
lished; the preclinical proﬁ  le of nilotinib as active drug against 
mutant BCR-ABL was largely conﬁ  rmed. Differences were 
noted in the PCRKL/CRKL blood baseline ratio between 
CML and Ph+ ALL, with values being lower in the latter 
subset of patients. The limitation of this assay is for advanced 
disease, where effective CRKL inhibition could reﬂ  ect dif-
ferential compartmentalization of the leukemic clone, when 
comparing CML and Ph+ ALL. Reactivation of BCR-ABL 
shortly after starting nilotinib treatment was seen in Ph+ 
ALL patients with progressive disease with p-loop mutations 
(Y253H, E255K) or T315I. This tool was suggested as a pos-
sible surrogate to establish effective dosing of nilotinib and to 
characterize resistance mechanisms (La Rosee et al 2008).
Activity of nilotinib against KIT 
and PDGFR malignancies
Nilotinib selectively inhibits Bcr-Abl, Kit, and PDGFR tyrosine 
kinases, but does not signiﬁ  cantly affect any of the kinases 
required for IL-3 signaling, such as JAK2, or a broad variety 
of other receptor tyrosine kinases or tyrosine kinase oncogenes 
(Weisberg et al 2005). These data also suggested that nilotinib 
can be a reasonable alternative therapy for the treatment of 
malignancies driven by mutated forms of Kit and PDGFR 
kinases, such as GIST (gastrointestinal stromal tumors) and 
hypereosinophilic syndromes (HES). Verstovsek et al dem-
onstrated that nilotinib is effective in HMC-1(560) mast cells 
carrying wild-type codon 816 c-kit, and is potent as imatinib in 
inhibiting cellular proliferation and in inducing apoptosis. By 
contrast, in HMC-1(560,816) cells bearing a c-kit mutation in 
codon 816, neither drug exerted a signiﬁ  cant effect. Nilotinib 
was also as effective as imatinib in inhibiting phosphorylation 
of c-kit in HMC-1(560) cells. Nilotinib had little effect on 
survival of bone marrow mast cells with 816 c-kit mutation 
obtained from patients with systemic mastocytosis (Verstovsek 
et al 2006a). Guo et al investigated on the efﬁ  cacy of second-
line tyrosine kinase inhibitors, such as sorafenib, dasatinib, and 
nilotinib, against the commonly observed imatinib-resistant 
Kit mutations [(Kit(V654A), Kit(T670I), Kit(D820Y), and 
Kit(N822K)] expressed in the Ba/F3 cellular system: they 
found that nilotinib inhibited the growth of imatinib-resistant 
cells carrying Kit(V560del/V564A) and Kit (V599D/D820Y) 
more efﬁ  caciously than dasatinib and sorafenib (Guo et al 
2007). However, nilotinib lacked activity against the mutant 
Kit (T670I) or double Kit (WK557-8del/T670I), resembling 
the lack of activity by imatinib, dasatinib, and nilotinib against OncoTargets and Therapy 2008:1 57
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the homologous T315I mutation (Guo et al 2007). Nilotinib 
was potent as imatinib in inducing apoptosis and inhibiting 
proliferation of EOL-1 cells, with IC(50) values of 0.54 nM. In 
addition, both imatinib and nilotinib inhibited the phosphoryla-
tion of PDGFR-alpha tyrosine kinase with equivalent efﬁ  cacy 
(Verstovsek et al 2006b). Stover et al proved that in vitro, 
nilotinib inhibited proliferation of Ba/F3 cells transformed by 
both TEL-PDGFRbeta and FIP1L1-PDGFRalpha with IC50 
values of less than 25 nM and inhibited phosphorylation of 
the fusion kinases and their downstream signaling targets. The 
imatinib mesylate-resistant mutant TEL-PDGFRbeta T681I 
was sensitive to nilotinib, whereas the analogous mutation in 
FIP1L1-PDGFRalpha, T674I, was resistant (Stover et al 2005). 
In contrast to these results is the experience of von Bubnoff, 
who proved nilotinib capable of suppressing the growth of 
Ba/F3 cells transfected with FIP1LI-PDGFRa harbouring the 
T674I mutation with an IC50 of 376 nM. This drug also induced 
apoptosis in T674I positive cells. The authors explained the con-
ﬂ  icting ﬁ  ndings by lower concentrations of nilotinib used in the 
experiments of Stover et al (2005) (von Bubnoff et al 2006).
Closing remarks
The current ﬁ  rst-line therapy for newly diagnosed CML 
patients is imatinib. However, imatinib resistance represents 
a signiﬁ  cant clinical problem that may not be overcome by an 
increase in dose. Novel inhibitors may work to some extent 
for imatinib-resistant patients. Nilotinib has been shown to 
be active in clinical phase II trials: data supported preclinical 
ﬁ  ndings demonstrating the high activity of this drug against 
BCR-ABL positive cells after failure of imatinib therapy 
owing to resistance or intolerance. The rational design of 
nilotinib was based on the scaffold of imatinib, resulting in 
a compound with increased afﬁ  nity and high potency against 
BCR-ABL mutants, except for T315I. Nilotinib has been 
approved by the FDA for the treatment of patients in CP 
or AP CML after failure with imatinib therapy. Studies on 
nilotinib as a ﬁ  rst-line therapy in early CP are in process and 
preliminary results suggest that this drug compares favorably 
with imatinib. Updates of these investigations are needed to 
conﬁ  rm the remarkable activity of nilotinib.
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